Synapse number is the best indicator of cognitive impairment In Alzheimer's disease (AD), yet the respective contributions of Aβ and tau, particularly human wild-type tau, to synapse loss remain undefined. Here, we sought to elucidate the Aβ-dependent changes in wild-type human tau that trigger synapse loss and cognitive decline in AD by generating two novel transgenic mouse models. The first overexpresses floxed human APP with Swedish and London mutations under the thy1 promoter, and recapitulates important features of early AD, including accumulation of soluble Aβ and oligomers, but no plaque formation. Transgene excision via Cre-recombinase reverses cognitive decline, even at 18-months of age. Secondly, we generated a human wild-type tauoverexpressing mouse. Crossing of the two animals accelerates cognitive impairment, causes enhanced accumulation and aggregation of tau, and results in reduction of dendritic spines compared to single transgenic hTau or hAPP mice. These results suggest that Aβ-dependent acceleration of wild-type human tau pathology is a critical component of the lasting changes to dendritic spines and cognitive impairment found in AD.
Introduction
Amyloid-beta (Aβ) and tau, the primary proteins implicated in Alzheimer's disease (AD) pathology, accumulate and form insoluble plaques and tangles, respectively (Querfurth and LaFerla, 2010) . The relationship between the toxic, soluble intermediates of these proteins and their impact on cognition, however, is poorly understood. Loss of excitatory synapses, as opposed to the plaque and tangle load, correlates with cognitive impairment in AD patients (DeKosky and Scheff, 1990; Terry et al., 1991) . Interestingly, the areas of synaptic loss are the same areas where neurodegeneration occurs, suggesting that neuronal loss is a secondary consequence of the same factors that trigger loss of synapses. Discerning the biological causes of early synaptic dysfunction in AD is a significant question in the field, as the downstream effects of protein accumulation, synapse loss and neurodegeneration have proved too extensive to properly treat with single therapeutics (Pillai and Cummings, 2013) .
Soluble Aβ oligomers are potent mediators of synaptotoxicity, and localize rapidly to the synapse in cultured neurons and mouse models of AD (Deshpande et al., 2006; Zempel et al., 2010) . Depending on the concentration and aggregation state, Aβ can either enhance presynaptic activity or depress post-synaptic activity through activation of multiple receptor pathways (Mucke and Selkoe, 2012) . Recent studies indicate that tau is a critical mediator of Aβ-induced synaptotoxicity, as removing endogenous tau from human APP mouse models prevents the cognitive deficits and synaptic loss found when murine tau is present (Roberson et al., 2007) . One proposed pathway by which tau may mediate synaptotoxicity is through interactions with the protein kinase Fyn. Tau binds Fyn, transporting it to the post-synaptic density where it phosphorylates the NR2B subunit of NMDARs, stabilizing the interaction between NMDARs and PSD-95 (Ittner et al., 2010; Lee et al., 1998; Salter and Kalia, 2004) . This stabilization could enhance Aβ induced toxicity through NMDARs. Importantly, knockdown of Fyn in Aβ-treated slice cultures and APP transgenic mice mitigates synaptic deficits (Chin et al., 2004; Lambert et al., 1998) .
Several studies have shown that Aβ promotes tau hyperphosphorylation and aggregation (Gotz et al., 2001; Lewis et al., 2001) . The triple transgenic 3xTg-AD model created in our laboratory greatly advanced the field in this area by providing an in vivo model with both Aβ and tau pathology, synaptic dysfunction, and cognitive decline with age. Using this model, we determined that Aβ pathology precedes tau pathology (Oddo et al., 2003) , and that immunotherapy targeting Aβ can ameliorate both Aβ and soluble tau pathology (Oddo et al., 2004) . However, all of these models utilize mutant forms of tau, begging the question whether the wild-type human form of tau found in AD is susceptible to the same Aβ driven mechanisms.
Here, we sought to elucidate the Aβ-dependent changes in wildtype human tau that cause synaptic loss and cognitive decline in AD, Neurobiology of Disease 64 (2014) [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] Abbreviations: AD, Alzheimer's disease; Aβ, amyloid-beta; APP, amyloid precursor protein.
